Novo Chops Wegovy Prices, but Doctors Still See Affordability Challenges for Patients

Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?

Key PointsPfizer's CEO thinks his company will make big waves in the weight loss market.Eli Lilly does have a strong hold on the industry and won't let go anytime soon.Even so, Lilly could carve out a niche in this and other areas, and eventually bounce back.10 stocks we like better than Pfizer › Oncology is the largest therapeutic area in the pharmaceutical industry by sales, but right now, weight management is the hottest. This market is predi…

GLP-1 price war heats up as Novo Nordisk offers $199 starter doses

With compounding pharmacies eating into sales, Novo Nordisk is betting big on its self-pay channel—and deep price cuts.

Novo Nordisk cuts Ozempic price in weight loss war with Eli Lilly

New discounts make Novo Nordisk’s weight loss drugs price-competitive with Eli Lilly’s competitor Zepbound

GLP-1 drug prices to dip

President Donald Trump unveiled a deal this month with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy.

Novo Nordisk slashes out-of-pocket prices for Wegovy and Ozempic for some customers

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy the weight-loss drug directly.

Drugmaker cuts prices for Ozempic, Wegovy. Here's how much you will pay.

The maker of the weight loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of the blockbuster medications.